Back to Search
Start Over
Risks of breast and ovarian cancer for women harboring pathogenic missense variants in BRCA1and BRCA2compared with those harboring protein truncating variants
- Source :
- Genetics in Medicine; January 2022, Vol. 24 Issue: 1 p119-129, 11p
- Publication Year :
- 2022
-
Abstract
- Germline genetic testing for BRCA1and BRCA2variants has been a part of clinical practice for >2 decades. However, no studies have compared the cancer risks associated with missense pathogenic variants (PVs) with those associated with protein truncating (PTC) variants.
Details
- Language :
- English
- ISSN :
- 10983600 and 15300366
- Volume :
- 24
- Issue :
- 1
- Database :
- Supplemental Index
- Journal :
- Genetics in Medicine
- Publication Type :
- Periodical
- Accession number :
- ejs58800176
- Full Text :
- https://doi.org/10.1016/j.gim.2021.08.016